Johnson & Johnson (JNJ) Friday reported positive Phase 3 ICONIC-TOTAL data for Icotrokinra, a once-daily oral peptide that selectively inhibits the IL-23 receptor.
The company noted that among adults and adolescents with at least moderate plaque psoriasis in high-impact areas, 57 percent of Icotrokinra-treated patients achieved clear or almost clear skin at Week 16 versus 6 percent on placebo.
Icotrokinra also delivered notable clearance in challenging regions: 66 percent achieved clear or almost clear scalp, and 77 percent reached minimal genital involvement. In a smaller hand/foot cohort, 42 percent responded versus 26 percent with placebo.
The treatment was well-tolerated, with similar adverse event rates to placebo and no new safety signals, underscoring its potential as a convenient, effective oral option for moderate-to-severe plaque psoriasis.
JNJ is currently trading at $155.43 down $0.24 or 0.15 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.